Images List Premium Download Classic

Dermatitis

Dermatitis-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Ophthalmic compositions
Laboratorios Salvat, S.a.
January 11, 2018 - N°20180008538

The present invention relates to a sterile ophthalmic composition comprising castor oil and a medium chain triglyceride, to its use in medicine, in particular for the treatment and/or prevention of an ocular disease selected from the group consisting of dry eye, conjunctivitis, dermatitis, blepharitis, entropion, floppy eyelid syndrome, thyroid ophthalmopathy, pterygium, conjunctivochalasis, epithelial damage induced by preservatives, epithelial or ...
Histone deacetylase inhibitors
Dana-farber Cancer Institute, Inc.
December 21, 2017 - N°20170360740

In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors. These compounds include an ester bond making them sensitive to deactivation by esterases. Therefore, these compounds are particularly useful in the treatment of skin disorders. When the compounds reaches the bloodstream, an esterase or an enzyme with esterase activity cleaves the compound ...
Systems and methods for reducing occupational dermatitis
Deb Ip Limited
December 14, 2017 - N°20170358149

A system for reducing occupational dermatitis at a work place the system comprising at a facility: one or more dispensers configured to dispense a pre-work hand product; one or more dispensers configured to dispense a washing or cleansing product; one or more dispensers configured to dispense a conditioning product; one or more dispensers configured to dispense a post-work product; a ...
Dermatitis Patent Pack
Download + patent application PDFs
Dermatitis Patent Applications
Download + Dermatitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Dermatitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Topical formulations of pde-4 inhibitors and their methods of use
Eisai R&d Management Co., Ltd.
December 07, 2017 - N°20170348311

Embodiments herein are directed to topical formulations of a compound represented by the formula (i), salt, metabolite, prodrug, or hydrate thereof along with a solvent, and a base. The compound is a pde4 inhibitor and the topical formulations may be used to treat dermatological conditions such as, but not limited to, atopic dermatitis, seborrheic dermatitis, alopecia, contact dermatitis, psoriasis, urticaria, ...
Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ror gamma (t))
Eisai R&d Management Co., Ltd.
November 30, 2017 - N°20170342062

Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of rorγt receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
Compositions and methods for topical treatment of tar responsive dermatological disorders
Neostrata Company, Inc.
November 30, 2017 - N°20170340667

Compositions and methods for treating tar-responsive dermatological disorders are described. In particular, an anhydrous tar composition including a liquid wax and a therapeutically effective amount of tar in an anhydrous solvent, the composition being in liquid form at room temperature is described. The anhydrous tar composition can be topically applied to skin of a subject for treatment of tar-responsive dermatological ...
Dermatitis Patent Pack
Download + patent application PDFs
Dermatitis Patent Applications
Download + Dermatitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Dermatitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Hydrophilic external gel formulation capable of enhancing skin permeability of tacrolimus
Chung-ang University Industry-academic Cooperation Foundation
November 30, 2017 - N°20170340558

The present invention relates to a formulation for external application to the skin containing tacrolimus, which is a poorly soluble drug used as a second therapeutic agent for atopic dermatitis and, more specifically, to a composition of a hydrophilic external gel formulation capable of enhancing skin permeability of tacrolimus, and a preparation method therefor. The hydrophilic external gel formulation loaded ...
Methods for treating atopic dermatitis by administering an il-4r antagonist
Sanofi Biotechnology
November 23, 2017 - N°20170333557

The present invention provides methods for treating atopic dermatitis (ad). Also provided are methods for improving one or more ad-associated parameter(s), and methods for decreasing the level of at least one ad-associated biomarker in a subject in need thereof. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-4 ...
Method of preparing mirabilitum praeparatum by pure strain fermentation and its applications
Sanofi Biotechnology
November 16, 2017 - N°20170326187

The present invention involves a method of preparing mirabilitum praeparatum by pure strain fermentation and its application in treating infectious and inflammatory diseases, as well as health products and cosmetics. The method involves blending the ripe fruit (watermelon) of citrullus lanatus (thumb.) matsumu. Et nakai with mirabilite (na2so4. 10h2o) according to a certain ratio as culture media and ...
Compound of the avermectin family or of the milbemycin family for the treatment and/or ...
Galderma Sa
October 26, 2017 - N°20170304340

A method of treating and/or preventing atopic dermatitis is described. The method includes use of a compound of the avermectin family, possibly ivermectin, or a compound of the milbemycin family in a pharmaceutically acceptable carrier.
Treatment of atopic dermatitis with indigo naturalis or indigo producing plant extract
Galderma S.a.
October 12, 2017 - N°20170290804

A pharmaceutical or cosmetic composition comprising an indigo naturalis or indigo-producing plant extract for treating atopic dermatitis and any form of eczema, and a method of treating atopic dermatitis comprising administering a therapeutically effective amount of an indigo naturalis or indigo-producing plant extract to a subject in need thereof are described.
Predicting allergic reactions
Alcyomics Ltd
October 05, 2017 - N°20170285001

This present invention provides a method of predicting immunogenicity and hypersensitivity or allergic reactions to chemical compounds, therapeutics, cosmetics and other chemical compositions. The method uses an in vitro assay employing autologous blood derived cells and an autologous cultured skin biopsy and is of particular utility in the identification and prediction of skin sensitizers that cause allergic contact dermatitis.
Therapeutic or prophylactic agent for itching skin diseases
Toray Industries, Inc.
October 05, 2017 - N°20170281727

An antimicrobial peptide ll-37 has an action to promote expression of a nerve repulsion factor sema3a. Ll-37 is a peptide composed of the c-terminal 37 residues of human cathelicidin hcap18. Use of this antimicrobial peptide enables normalization of expression of axon guidance molecules such as nerve repulsion factor in lesions of pruritic dermatoses including atopic dermatitis and xeroderma, and thus ...
Dermatitis Patent Pack
Download + patent application PDFs
Dermatitis Patent Applications
Download + Dermatitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Dermatitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Galderma S.a.
October 05, 2017 - N°20170281663

Dermatological conditions/afflictions such as rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acneform rashes, transient acantholytic dermatosis, and acne necrotica miliaris, most notably rosacea, are treated by topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises a thus effective amount of ivermectin.
Methods of treating skin disorders using anti-il-31ra antibodies
Zymogenetics, Inc.
September 28, 2017 - N°20170275369

The present invention relates to methods of treating patients suffering from contact dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous t cell lymphoma, bullous pemphigoid, alopecia aereata, vitiligo, acne rosacea, prurigo nodularis, scleroderma, herpes simplex virus, or combination by administering an il-31ra antagonist.
Compounds as crth2 antagonist and uses thereof
Sunshine Lake Pharma Co., Ltd.
September 21, 2017 - N°20170267634

The compounds of formula (i) which can be used as crth2 receptor antagonists are provided. The compounds of formula (i) can be used in the treatment and prevention of asthma, allergic rhinitis and atopic dermatitis, as well as other diseases mediated by prostaglandin d2 (pgd2) at the crth2 receptor.
Negative hydrogen ion intellegrnt filtration system for curing cancer, cardiovascular disease, diabetes, hypertension, nephrotic syndrome, ...
Mega Sun Biomedical Corp.
September 21, 2017 - N°20170267563

A negative hydrogen ion intelligent filtration system includes a housing; a filtering mechanism disposed in the housing and comprising a first filter, a second filter connected to the first filter, a third filter connected to second filter, a fourth filter connected to the third filter, a fifth filter connected to the fourth filter, a sixth filter connected to the fifth ...
Modulation of tissue transglutaminase activation in disease
The Board Of Trustees Of The Leland Stanford Junior University
September 21, 2017 - N°20170266198

Compositions and methods are provided for modulating the physiological activation of tissue transglutaminase (tg2); which methods can include inhibiting the activation of tg2 associated with enteric inflammatory disorders, which disorders may include celiac disease, irritable bowel syndrome, crohn's disease, dermatitis herpetiformis, and the like. In other embodiments of the invention, methods are provided for reducing undesirable paracellular transport in enteric ...
Methods of treating atopic dermatitis with il-31 monoclonal antibodies
Zymogenetics, Inc.
September 14, 2017 - N°20170260267

The present invention relates to methods of treating pruritic diseases, including but not limited to contact dermatitis, atopic dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous t cell lymphoma, bullous pemphigoid, alopecia wereata, vitiligo, acne rosacea, prurigo nodularis, scleroderma, herpes simplex virus, or combination thereof by administering il-31 monoclonal antibodies. The invention further provides the hybridomas ...
Compositions comprising dihydroquercetin for use in methods for treating the effects associated with skin inflammatory ...
Bionoox Suisse Sa
August 31, 2017 - N°20170246141

A method of using a composition including dihydroquercetin, as well as optionally α-tocopherol and/or bisabolol, for treating the effects associated with skin inflammatory disorder, such as those associated with diseases characterized by inappropriate immune response, such as psoriasis, atopic dermatitis and/or urticaria. A process of manufacturing the composition is also described.
Chemical inhibitors of sebocyte function
Bionoox Suisse Sa
August 24, 2017 - N°20170240575

The present discovery pertains to the discovery of certain amphiphilic compounds that may be useful for the management of sebum secretion in subjects with acne, oily skin, or seborrheic dermatitis. These compounds are 1-dialkylphosphorylalkanes with the longest alkyl group being seven or more carbons. Preferably, a compound is dissolved in a dermatologically acceptable vehicle, and delivered to the skin in ...
Loading